The Patent Finder
MT

Magenta Therapeutics, Inc.

First filing 2015
OverviewNotableFeesChangesFamiliesPatent listSources & methods

2 patents currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2036. from the record

Of the 15 now held by other companies, 5 name Regeneron Pharmaceuticals Inc. as their current owner, and 10 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2036
Next term end
2
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.

Formerly held, still cited

Notable
Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2034.
Ends Sep 2034 · High confidence
Also notable
The most cited patent in this portfolio, cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Ends Apr 2038 · High confidence
Also notable
Cited by 7 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039.
Ends Mar 2039 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Compositions and Methods for the Depletion of CD117+ Cells (US 11,958,908) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,781,259Modified Antibodies and Related Compounds, Compositions, and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,958,908Compositions and Methods for the Depletion of CD117+ Cells
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 2: 15 patents in force now held by others · 2 patents ended · 6 applications pending · 38 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited